CytoSorbents Announces Start of $1M US Army Phase II SBIR Contract
Also announces additional funding […]
Also announces additional funding […]
Mr. James R. Nowodworski […]
COTI‐2 demonstrates activity against many common p53 gene mutations […]
Al Amir SE #17 Development well tests at a gross rate of 3,664 bopd and Shehab-2 Exploration Well Spudded. […]
Interview with Charlie Mollo, CEO […]
Interview with Paul Thompson, CEO […]
WITH HITIT MEDICAL SYSTEMS IN TURKEY […]
By Brian Marckx, CFA […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com